These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

165 related items for PubMed ID: 15905710

  • 1. The case for using 5-aminosalicyclates in Crohn's disease: pro.
    Hanauer SB.
    Inflamm Bowel Dis; 2005 Jun; 11(6):609-12. PubMed ID: 15905710
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Aminosalicylates for induction of remission or response in Crohn's disease.
    Lim WC, Hanauer S.
    Cochrane Database Syst Rev; 2010 Dec 08; (12):CD008870. PubMed ID: 21154400
    [Abstract] [Full Text] [Related]

  • 5. The case against using 5-aminosalicyclates in Crohn's disease: con.
    Stange EF.
    Inflamm Bowel Dis; 2005 Jun 08; 11(6):613-5. PubMed ID: 15905711
    [No Abstract] [Full Text] [Related]

  • 6. Mesalamine derivatives in the treatment of Crohn's disease.
    Harrell LE, Hanauer SB.
    Gastroenterol Clin North Am; 2004 Jun 08; 33(2):303-17, ix-x. PubMed ID: 15177540
    [Abstract] [Full Text] [Related]

  • 7. [Ulcerous colitis and Crohn's disease in members of one family: case description and review of literature].
    Neĭman KP, Rumiantsev VG.
    Eksp Klin Gastroenterol; 2006 Jun 08; (3):56-60. PubMed ID: 17203844
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Efficacy of 5-aminosalicylates in Crohn's disease: systematic review and meta-analysis.
    Ford AC, Kane SV, Khan KJ, Achkar JP, Talley NJ, Marshall JK, Moayyedi P.
    Am J Gastroenterol; 2011 Apr 08; 106(4):617-29. PubMed ID: 21407190
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Comparative Effectiveness of Mesalamine, Sulfasalazine, Corticosteroids, and Budesonide for the Induction of Remission in Crohn's Disease: A Bayesian Network Meta-analysis.
    Coward S, Kuenzig ME, Hazlewood G, Clement F, McBrien K, Holmes R, Panaccione R, Ghosh S, Seow CH, Rezaie A, Kaplan GG.
    Inflamm Bowel Dis; 2017 Mar 08; 23(3):461-472. PubMed ID: 28146003
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Drug insight: aminosalicylates for the treatment of IBD.
    Nielsen OH, Munck LK.
    Nat Clin Pract Gastroenterol Hepatol; 2007 Mar 08; 4(3):160-70. PubMed ID: 17339853
    [Abstract] [Full Text] [Related]

  • 19. Controversies with aminosalicylates in inflammatory bowel disease.
    Lim WC, Hanauer SB.
    Rev Gastroenterol Disord; 2004 Mar 08; 4(3):104-17. PubMed ID: 15359211
    [Abstract] [Full Text] [Related]

  • 20. Mesalamine in the treatment of active Crohn's disease.
    Dignass A, Marteau P.
    Gastroenterology; 2005 Jan 08; 128(1):245-6; author reply 246. PubMed ID: 15633152
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.